Robert Z. Orlowski, MD, PhD - The New ABCs of Myeloma Care: Enhancing Outcomes With CD38 Antibodies, BCMA Immunotherapy, and Unique Bispecific Platforms

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast

Go online to PeerView.com/HZN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The expanding use of CD38 antibodies, CAR-T, and BCMA and non-BCMA treatment options has quickly changed the clinical conversation for modern multiple myeloma (MM) management. Are you prepared for the new “ABCs” of myeloma care? Find out by accessing this PeerView MasterClass and Case Forum event developed in collaboration with the HealthTree Foundation for Multiple Myeloma and recorded at the 2023 ASCO Annual Meeting. During this activity, our experts provide insights and case-based guidance on therapy selection, dosing, scheduling, and management of treatment-related AEs with CD38 antibodies and BCMA platforms in MM. Learn the real-world “ABCs” of treatment innovation in MM, and take your patient care to the next level! Upon completion of this activity, participants should be better able to: Summarize the unique MOA and safety/efficacy evidence supporting the use of CD38 and BCMA-targeting antibodies, CAR-T therapy, and other innovative compounds across multiple myeloma treatment settings; Develop personalized upfront and sequential treatment plans with innovative antibody and immunotherapy platforms, based on relevant prognostic information and safety considerations; and Address practical aspects of multiple myeloma care when using antibody and immunotherapy platforms, including dosing, scheduling, patient referral to specialized care, education, counseling, and unique treatment-related toxicities